Private Equity Round in 2022
Global R&D organization specializing in patient-derived stem cells and primary cells
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company's lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate aimed at treating soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, a CAB ADC targeted at non-small cell lung cancer and melanoma, as well as BA3071, which is an anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers including renal cell carcinoma and bladder cancer. Utilizing proprietary platforms for antibody discovery and optimization, BioAtla aims to create safer and more effective cancer treatments by enhancing selectivity for tumor tissues while minimizing effects on normal tissues. The company holds over 150 issued patents and applications related to its innovative therapeutic approaches, which have the potential to address previously untreatable cancers.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.
Private Equity Round in 2019
Bionova Scientific, Inc. was founded by a group of biopharmaceutical specialists and is located in Fremont, CA. This biologics company presents services for cell line development including new biological entity (NBEs) and Biosimilars, cell culture process development, as well as scale- up and tech transfer support in generating biologic medical products.
Private Equity Round in 2019
Axiom Real-Time Metrics Inc. develops an eClinical software that provides solutions and services to small and medium life sciences organizations. The company’s software focuses on electronic data capture ("EDC"), data management ("DM"), clinical trial management systems ("CTMS"), randomization ("IWRS"), electronic patient reported outcomes ("ePRO"), and other technology and service solutions for biotechnology and pharmaceutical sponsors conducting clinical trials. Its services include eClinical management, biostats, pharmacovigilance, and training. The company was founded in 2001 and is based in Toronto, Canada.
Nebula Genomics, founded in 2016 by Harvard genomics pioneer George Church and researchers Dennis Grishin and Kamal Obbad, operates an online marketplace for genomic and health data based in San Francisco, California. The company aims to facilitate genomic sequencing and health data sharing by allowing consumers to maintain control over their personal information and receive compensation for its use. By utilizing blockchain technology, Nebula Genomics eliminates intermediaries, enabling direct access to a rich repository of genetic data. This aggregated information serves researchers and the medical community, enhancing drug development and clinical trials while promoting personalized medicine. The company is supported by investors such as Khosla Ventures and Arch Venture Partners, and it also has a presence in Boston, Massachusetts.
CSM solves complex clinical trial supply problems for biotech and pharmaceutical companies such as limited drug supply, time constraints and mid-study changes. They offer a unique blend of traditional and innovative services that can significantly shorten timelines, reduce costs and improve outcomes for clinical studies.
Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.
Bovie Medical Corporation manufactures digital electrosurgical generators and accessories for the operating room and surgicenter. It is also a producer of battery-operated cauteries in the world. Its technology is a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision and minimal invasiveness.
HRAA interprets data to ensure that healthcare is efficient and effective for everyone by pulling medical data together to create a predictive window to understand cost and revenues looking back and going forward. Founded in 2001 and based out of Plantation, FL, HRAA combines years of industry expertise with best-in-breed technology to create market leading business intelligence products and consulting services to ensure hospitals are reimbursed for every pill they prescribe, every procedure they perform and every test they administer. HRAA both trains and supplies the high tech workforce to hospitals to generate the predictive data used by the whole healthcare system and offers a full suite of solutions needed to keep up with the ever-changing healthcare industry including data analytics software, business intelligence technology, medical coding, auditing, education, revenue cycle consulting, and ICD-10 transition solutions.
Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.
Private Equity Round in 2013
iVantage Health Analytics is a leading advisory and business analytic services company, applying Accelerated Healthcare Transformation and the integrated VantagePoints platform of solutions to drive sustained, evidence based results for healthcare clients. The company's unique combination of technology, content, and expert advisory services accelerates decision making for the new healthcare.
Connecture, Inc. provides Web-based sales, service, and process automation solutions to the private Medicare insurance industry, including Medicare Advantage and Prescription Drug Plans. The company offers the PlanCompare and DrugCompare product suites, via SaaS installations for Medicare carriers and PBMs. It also provides on-site software installation and integration, and managed hosting solutions, as well as customer support services for health insurance companies. Connecture, Inc. divested its non-Medicare insurance products and now focuses exclusively on Medicare insurers and PBMs, originally served by acquired company DRX. The company was acquired by Harris Computer Systems in October, 2019 and is headquartered in Milwaukee, Wisconsin.
Private Equity Round in 2011
Aris provides professional radiology services to patients, surgeons and healthcare institutions. The Company is a Joint Commission certified radiology services company. The Company works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution to its clients by providing high quality radiologists, 24/7 sub specialty coverage, 24/7 operations support, and quality assurance data. Aris' breadth of service and discipline allows it to deliver high quality patient care in a cost effective manner to the hospitals, and other health care payors.
WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.
Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.
American Surgical Professionals is a provider of professional surgical assistant services to hospitals, clinics, surgeons and patients. American Surgical Professionals offers custom tailored solutions to perioperative staffing situations. These include providing surgical specialists on an outsourced, as needed or contract basis.
Cytovance Biologics is a full service CDMO specializing in cGMP production of therapeutic proteins & antibodies from mammalian cell culture (CHO), microbial fermentation (Ecoli), and transgenic processes. We offer cell line development, process development services, purification development, stability testing, and more from our FDA inspected, Oklahoma City state-of-the-art facilities.
Solta Medical - Medical Aesthetic Devices > Splash
BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.
Solta Medical - Medical Aesthetic Devices > Splash
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.
Private Equity Round in 2008
Biotronic will continue to lead the intraoperative neural monitoring industry with our breadth of services, patient-centric focus, clinical research & education, geographic concentration and reach, and financial performance. In pursuit of our mission & vision, Biotronic has assembled the clinical expertise and organizational capabilities needed to provide excellence in care and prompt, reliable service with managed cost efficiency. As experts in this specialty, we take pride in partnering with hospitals and surgeons to obtain and analyze critical information during selective surgeries which place neural structures at risk. The information we provide allows surgeons to intervene immediately to mitigate problems that may otherwise go undetected until after completion of the surgery. We help you improve your quality and do so within a cost-effective partnership.
As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The companys discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.
Forbes Medi-Tech Inc. is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products.